

博士課程修了者学位論文リスト (2002-2015)

1. **Nogami A*, Oshikawa G, Okada K, Fukutake S, Umezawa Y, Nagao T, Kurosu T, Miura O:** FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. *Oncotarget* 6:9189-9205, 2015.
2. **Suwa S*, Kasubata A, Kato M, Iida M, Watanabe K, Miura O, Fukuda T:** The tryptophan derivative, tranilast, and conditioned medium with indoleamine 2,3-dioxygenase-expressing cells inhibit the proliferation of lymphoid malignancies. *Int J Oncol* 46:1369-1376, 2015.
3. **Wang L*, Sato-Otsubo A, Sugita S, Takase H, Mochizuki M, Usui Y, Goto H, Koyama T, Akiyama H, Miura O, Ogawa S, Arai A:** High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays. *Cancer Sci* 105:592-599, 2014.
4. **Nakaima Y, Watanabe K*, Koyama T, Miura O, Fukuda T:** CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-kappaB activation. *PLoS One* 8:e64425, 2013.
5. **Wu N*, Kurosu T, Oshikawa G, Nagao T, Miura O:** PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. *Int J Oncol* 42:419-428, 2013.
6. **Ichikawa A*, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y, Nakashima S, Sugita Y, Miura O, Ohshima K:** Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. *Eur J Haematol* 91:20-28, 2013.
7. **Oshikawa G*, Nagao T, Wu N, Kurosu T, Miura O:** c-Cbl and Cbl-b ligases

mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. *J Biol Chem* 286:30263-30273, 2011.

8. **Nagao T*, Oshikawa G, Wu N, Kurosu T, Miura O:** DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3beta. *PLoS One* 6:e27397, 2011.
9. **Kurosu T, Ohki M*, Wu N, Kagechika H, Miura O:** Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. *Cancer Res* 69:3927-3936, 2009.
10. **Yan W*, Arai A, Aoki M, Ichijo H, Miura O:** ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis. *Biochem Biophys Res Commun* 355:1038-1044, 2007.
11. **Teng Y*, Takahashi Y, Yamada M, Kurosu T, Koyama T, Miura O, Miki T:** IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells. *Eur J Cell Biol* 86:581-589, 2007.
12. **Kida A*, Kakihana K, Kotani S, Kurosu T, Miura O:** Glycogen synthase kinase-3beta and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells. *Oncogene* 26:6630-6640, 2007.
13. **Jin A*, Kurosu T, Tsuji K, Mizuchi D, Arai A, Fujita H, Hattori M, Minato N, Miura O:** BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion. *Oncogene* 25:4332-4340, 2006.
14. **Iiyama M*, Kakihana K, Kurosu T, Miura O:** Reactive oxygen species generated by hematopoietic cytokines play roles in activation of

receptor-mediated signaling and in cell cycle progression. *Cell Signal* 18:174-182, 2006.

15. **Morita Y*, Hosokawa M, Ebisawa M, Sugita T, Miura O, Takaue Y, Heike Y:** Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 36:803-811, 2005.
16. **Kakahana K*, Yamamoto M, Iiyama M, Miura O:** Calmodulin physically interacts with the erythropoietin receptor and enhances Jak2-mediated signaling. *Biochem Biophys Res Commun* 335:424-431, 2005.
17. **Jin ZH*, Kurosu T, Yamaguchi M, Arai A, Miura O:** Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. *Oncogene* 24:1973-1981, 2005.
18. **Yamamoto M*, Kurosu T, Kakihana K, Mizuchi D, Miura O:** The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. *Biochem Biophys Res Commun* 319:1272-1275, 2004.
19. **Haraguchi K*, Takahashi T, Hiruma K, Kanda Y, Tanaka Y, Ogawa S, Chiba S, Miura O, Sakamaki H, Hirai H:** Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 34:595-602, 2004.
20. **Kurosu T*, Fukuda T, Miki T, Miura O:** BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. *Oncogene* 22:4459-4468, 2003.
21. **Kanda E*, Jin ZH, Mizuchi D, Arai A, Miura O:** Activation of Rac and tyrosine phosphorylation of cytokine receptors induced by cross-linking of integrin alpha4beta1 and cell adhesion in hematopoietic cells. *Biochem Biophys Res Commun* 301:934-940, 2003.

22. **Sakashita C*, Fukuda T, Okabe S, Kobayashi H, Hirosawa S, Tokuhisa T, Miyasaka N, Miura O, Miki T:** Cloning and characterization of the human BAZF gene, a homologue of the BCL6 oncogene. *Biochem Biophys Res Commun* 291:567-573, 2002.

*学位取得者

研究指導委託

6. 久留米大学医学部 大島孝一教授
15. 国立がんセンター 高上洋一博士
19. 東京大学大学院 平井久丸教授